Literature DB >> 22092395

Nuclear atypia grading score is a useful prognostic factor in papillary gastric adenocarcinoma.

Yuichiro Nakashima1, Takashi Yao, Minako Hirahashi, Shinichi Aishima, Yoshihiro Kakeji, Yoshihiko Maehara, Masazumi Tsuneyoshi.   

Abstract

AIMS: To investigate nuclear atypical in papillary gastric adenocarcinoma (PGA). METHOD AND
RESULTS: Hundred cases of PGA were classified into two groups according to nuclear pleomorphism and nuclear polarity; these groups were designated as high nuclear grade and low nuclear grade. Correlations between nuclear grade and clinicopathological features were evaluated for prognostic value. In order to evaluate which types of biological factors influence nuclear atypia, the expression of gastric-type mucin phenotype, p53, HER2 and Ki-67 detected by immunohistochemistry and DNA ploidy detected by laser scanning cytometry. The high nuclear grade group correlated with deeper wall invasion, the presence of lymphatic and venous invasion and the positivity of lymph node metastasis. High nuclear grade was an independent prognostic factor for disease-free survival. Moreover, significant correlations were observed between high nuclear grade and positivity of gastric-type mucin phenotype, p53 and HER2 and DNA aneuploidy.
CONCLUSION: Nuclear grade could be a new and useful morphological predictor for high malignant potential in PGA.
© 2011 Blackwell Publishing Limited.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22092395     DOI: 10.1111/j.1365-2559.2011.04035.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  8 in total

1.  Microtubule-organizing center-mediated nuclear polarity in various normal and neoplastic human tissues.

Authors:  Shin-Ichi Murata; Kenji Warigaya; Ibu Matsuzaki; Masahiro Itonaga; Yuki Shimizu; Masayo Shuto
Journal:  Virchows Arch       Date:  2015-03-06       Impact factor: 4.064

2.  Lymphovascular invasion and lymph node metastasis rates in papillary adenocarcinoma of the stomach: implications for endoscopic resection.

Authors:  Byung-Hoon Min; Sun-Ju Byeon; Jun Haeng Lee; Kyoung-Mee Kim; Ji Yeong An; Min Gew Choi; Jun Ho Lee; Tae Sung Sohn; Jae Moon Bae; Sung Kim
Journal:  Gastric Cancer       Date:  2017-12-26       Impact factor: 7.370

3.  Association of HER2 gene amplification and tumor progression in early gastric cancer.

Authors:  Kazuki Kanayama; Hiroshi Imai; Eri Usugi; Taizo Shiraishi; Yoshifumi S Hirokawa; Masatoshi Watanabe
Journal:  Virchows Arch       Date:  2018-08-17       Impact factor: 4.064

Review 4.  Clinicopathologic significance and prognostic value of Ki-67 expression in patients with gastric cancer: a meta-analysis.

Authors:  Guanying Luo; Yunzhao Hu; Zhiqiao Zhang; Peng Wang; Zhaowen Luo; Jinxin Lin; Canchang Cheng; You Yang
Journal:  Oncotarget       Date:  2017-07-25

5.  Induction of microRNA‑let‑7a inhibits lung adenocarcinoma cell growth by regulating cyclin D1.

Authors:  Wei Zhao; Jin-Xia Hu; Rui-Min Hao; Qian Zhang; Jun-Qi Guo; You-Jie Li; Ning Xie; Lu-Ying Liu; Ping-Yu Wang; Can Zhang; Shu-Yang Xie
Journal:  Oncol Rep       Date:  2018-07-24       Impact factor: 3.906

6.  Nuclear shape, architecture and orientation features from H&E images are able to predict recurrence in node-negative gastric adenocarcinoma.

Authors:  Meng-Yao Ji; Lei Yuan; Xiao-Da Jiang; Zhi Zeng; Na Zhan; Ping-Xiao Huang; Cheng Lu; Wei-Guo Dong
Journal:  J Transl Med       Date:  2019-03-18       Impact factor: 5.531

7.  Ki-67/MKI67 as a Predictive Biomarker for Clinical Outcome in Gastric Cancer Patients: an Updated Meta-analysis and Systematic Review involving 53 Studies and 7078 Patients.

Authors:  Dan-Dan Xiong; Chu-Mei Zeng; Ling Jiang; Dian-Zhong Luo; Gang Chen
Journal:  J Cancer       Date:  2019-08-29       Impact factor: 4.207

8.  Computational analysis of morphological and molecular features in gastric cancer tissues.

Authors:  Yoko Yasuda; Kazuaki Tokunaga; Tomoaki Koga; Chiyomi Sakamoto; Ilya G Goldberg; Noriko Saitoh; Mitsuyoshi Nakao
Journal:  Cancer Med       Date:  2020-02-03       Impact factor: 4.452

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.